St. Jude Medical Inc. is looking to accelerate sales growth in the coming years with the aid of key pipeline projects beyond its core cardiac rhythm management business as CRM continues to face market weakness, the firm told investors Feb. 3 during its annual investor meeting in New York.
Among significant devices in development are the firm’s Portico transcatheter aortic heart valve, a percutaneous mitral valve repair device, a renal denervation system for drug-resistant hypertension, the Amplatzer cardiac plug...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?